YolTech Therapeutics reports positive clinical data for YOLT-203, an in vivo gene editing therapy for primary hyperoxaluria type 1: Shanghai, China Wednesday, February 26, 2025, 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback